The First Us Study to Assess the Feasibility and Safety of Endocardial Delivery of Allogenic Mesenchymal Precursor Cells in Patient With Heart Failure: Three-Month Interim Analysis

Dib, Nabil; Henry, Tim; Maria, Anthony De; Itescu, Silviu; McCarthy, Megan; Jaggar, Susan; Taylor, N C; Campbell, Ann; Krum, Henry; Bartels, Kendra; Skerrett, Donna; Perin, Emerson C.

doi:10.1016/s0735-1097(10)62049-9

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To that end, MSCs, which are purportedly immunoprivileged, have attracted interest; clinical trials involving the administration of proprietary allogeneic human MSCs to patients with heart disease are already under way, and the preliminary results have been encouraging. 137,138 It should be noted that, without immunosuppression or HLA matching, most allogeneic cells (even MSCs) will eventually be rejected after in vivo transplantation. 139 -142 Nevertheless, since the vast majority of the observed functional benefit is attributable to indirect pathways, rejection of allogeneic cells may not be an issue if it is delayed long enough to allow them to exert their protective and regenerative paracrine effects.…”

Section: Use Of Allogeneic Cellsmentioning

confidence: 99%

Cardiac cell therapy: where we've been, where we are, and where we should be headed

Malliaras

Marbán

2011

British Medical Bulletin

177

157

View full text Add to dashboard Cite

The cardiogenic potential of bone marrow-derived cells, the mechanism whereby small numbers of poorly-retained cells translate to measurable clinical benefit, and the overall impact on clinical outcomes are hotly debated. GROWING POINTS/AREAS TIMELY FOR DEVELOPING RESEARCH: This overview of the field leaves us with cautious optimism, while motivating a search for more effective delivery methods, better strategies to boost cell engraftment, more apt patient populations, safe and effective 'off the shelf' cell products and more potent cell types.

show abstract

Section: Use Of Allogeneic Cellsmentioning

confidence: 99%

Cardiac cell therapy: where we've been, where we are, and where we should be headed

Malliaras

Marbán

2011

British Medical Bulletin

177

157

View full text Add to dashboard Cite

show abstract

“…Human MSCs and ESCs may have lower immunogenicity in vivo than cells from other species. Clinical programs involving the administration of proprietary allogeneic human MSCs to patients with heart disease are under way (75,76). The launching of such programs has been based almost exclusively on the initial presumption of the immunotolerance of allogeneic stem cells.…”

Section: Discussionmentioning

confidence: 99%

“…The launching of such programs has been based almost exclusively on the initial presumption of the immunotolerance of allogeneic stem cells. To date, adverse effects or safety issues associated with the use of allogeneic MSCs have not been reported in clinical trials (32,(75)(76)(77), although cellular and humoral responses in the myocardium have not been well studied.…”

Section: Discussionmentioning

confidence: 99%

Immunologic and Inflammatory Reactions to Exogenous Stem Cells

Buja

Vela

2010

Journal of the American College of Cardiology

View full text Add to dashboard Cite

Intense research is under way to determine the optimal stem cell type and regimen for repairing diseased myocardium. Although initial studies in humans focused on the use of homologous stem cells, allogeneic or xenogeneic stem cells have been studied extensively in experimental work. Clinical trials with allogeneic stem cells are now under way, an approach based on the premise that stem cells and precursor cells are characterized as being immunotolerant. However, evidence indicates that stem cells may gain immune potency in vivo, especially when delivered to inflamed tissue, such as acutely infarcted myocardium. Histopathologic studies show the presence of a lymphohistiocytic inflammatory reaction at the sites of delivery of allogeneic stem cells, a response that is exaggerated with the use of xenogeneic stem cells. The immune-mediated inflammatory reaction to allogeneic and xenogeneic stem cells may elicit a spectrum of effects, ranging from beneficial (e.g., increased paracrine activity) to detrimental (e.g., accelerated damage and removal of stem cells). Although the issue of immune-mediated inflammatory responses to non-self stem cells requires further evaluation, non-self stem cells should not be considered as immunologically inert or exclusively immunosuppressive in vivo.

show abstract

“…Analysis of the data obtained after 6 months of followup ( http://www.mesoblast.com/newsroom/asx-announcements/archives/ ) showed a significant decrease in the number of patients who developed any severe or major adverse cardiac event, such as composite of cardiac death, heart attack, or need for coronary revascularization procedures. Moreover, the first cohort in the study ( n = 20 patients), which received the low dose of the cell treatment, showed a significantly greater increase in the EF when compared with the control group [ 123 ].…”

Section: Mesenchymal Progenitors and Clinical Applicationmentioning

confidence: 99%

Mesenchymal Stem Cells and Cardiovascular Disease: A Bench to Bedside Roadmap

Mazo

Araña

Pelacho

et al. 2012

Stem Cells International

View full text Add to dashboard Cite

In recent years, the incredible boost in stem cell research has kindled the expectations of both patients and physicians. Mesenchymal progenitors, owing to their availability, ease of manipulation, and therapeutic potential, have become one of the most attractive options for the treatment of a wide range of diseases, from cartilage defects to cardiac disorders. Moreover, their immunomodulatory capacity has opened up their allogenic use, consequently broadening the possibilities for their application. In this review, we will focus on their use in the therapy of myocardial infarction, looking at their characteristics, in vitro and in vivo mechanisms of action, as well as clinical trials.

show abstract

The First Us Study to Assess the Feasibility and Safety of Endocardial Delivery of Allogenic Mesenchymal Precursor Cells in Patient With Heart Failure: Three-Month Interim Analysis

Cited by 4 publications

References 0 publications

Cardiac cell therapy: where we've been, where we are, and where we should be headed

Cardiac cell therapy: where we've been, where we are, and where we should be headed

Immunologic and Inflammatory Reactions to Exogenous Stem Cells

Mesenchymal Stem Cells and Cardiovascular Disease: A Bench to Bedside Roadmap

Contact Info

Product

Resources

About